MREO
Price
$1.75
Change
-$0.01 (-0.57%)
Updated
Aug 28 closing price
Capitalization
279.84M
81 days until earnings call
RGNX
Price
$9.01
Change
+$0.19 (+2.15%)
Updated
Aug 28 closing price
Capitalization
455.13M
68 days until earnings call
Interact to see
Advertisement

MREO vs RGNX

Header iconMREO vs RGNX Comparison
Open Charts MREO vs RGNXBanner chart's image
Mereo BioPharma Group
Price$1.75
Change-$0.01 (-0.57%)
Volume$545.91K
Capitalization279.84M
REGENXBIO
Price$9.01
Change+$0.19 (+2.15%)
Volume$445.57K
Capitalization455.13M
MREO vs RGNX Comparison Chart in %
Loading...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MREO vs. RGNX commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MREO is a Buy and RGNX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (MREO: $1.75 vs. RGNX: $9.01)
Brand notoriety: MREO and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MREO: 21% vs. RGNX: 67%
Market capitalization -- MREO: $279.84M vs. RGNX: $455.13M
MREO [@Biotechnology] is valued at $279.84M. RGNX’s [@Biotechnology] market capitalization is $455.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MREO’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 0 green FA rating(s).

  • MREO’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 0 green, 5 red.
According to our system of comparison, RGNX is a better buy in the long-term than MREO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MREO’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 7 bullish TA indicator(s).

  • MREO’s TA Score: 4 bullish, 3 bearish.
  • RGNX’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than MREO.

Price Growth

MREO (@Biotechnology) experienced а +6.06% price change this week, while RGNX (@Biotechnology) price change was +11.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.11%. For the same industry, the average monthly price growth was +20.33%, and the average quarterly price growth was +29.99%.

Reported Earning Dates

MREO is expected to report earnings on Nov 18, 2025.

RGNX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($455M) has a higher market cap than MREO($280M). RGNX YTD gains are higher at: 16.559 vs. MREO (-50.000). MREO has higher annual earnings (EBITDA): -47.49M vs. RGNX (-129.93M). RGNX has more cash in the bank: 323M vs. MREO (56.1M). MREO has less debt than RGNX: MREO (601K) vs RGNX (77.7M). RGNX has higher revenues than MREO: RGNX (156M) vs MREO (500K).
MREORGNXMREO / RGNX
Capitalization280M455M62%
EBITDA-47.49M-129.93M37%
Gain YTD-50.00016.559-302%
P/E RatioN/AN/A-
Revenue500K156M0%
Total Cash56.1M323M17%
Total Debt601K77.7M1%
FUNDAMENTALS RATINGS
MREO vs RGNX: Fundamental Ratings
MREO
RGNX
OUTLOOK RATING
1..100
137
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8655
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGNX's Valuation (71) in the Biotechnology industry is in the same range as MREO (75) in the null industry. This means that RGNX’s stock grew similarly to MREO’s over the last 12 months.

RGNX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MREO (100) in the null industry. This means that RGNX’s stock grew similarly to MREO’s over the last 12 months.

RGNX's SMR Rating (100) in the Biotechnology industry is in the same range as MREO (100) in the null industry. This means that RGNX’s stock grew similarly to MREO’s over the last 12 months.

RGNX's Price Growth Rating (55) in the Biotechnology industry is in the same range as MREO (86) in the null industry. This means that RGNX’s stock grew similarly to MREO’s over the last 12 months.

RGNX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MREO (100) in the null industry. This means that RGNX’s stock grew similarly to MREO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MREORGNX
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 7 days ago
77%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
Bearish Trend 11 days ago
84%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
66%
View a ticker or compare two or three
Interact to see
Advertisement
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EVSTX22.59N/A
N/A
Allspring Disciplined US Core C
FWOAX17.95N/A
N/A
Fidelity Advisor Women's Leadership A
LASGX16.27N/A
N/A
Lord Abbett International Growth R4
HQIIX21.63N/A
N/A
Hartford Equity Income I
IGHAX12.53N/A
N/A
Voya Global High Dividend Low Vol Port A

MREO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been closely correlated with RARE. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if MREO jumps, then RARE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
-0.57%
RARE - MREO
69%
Closely correlated
+0.73%
TRDA - MREO
43%
Loosely correlated
-0.53%
CRNX - MREO
39%
Loosely correlated
+0.82%
NRIX - MREO
38%
Loosely correlated
-1.47%
RGNX - MREO
34%
Loosely correlated
+2.15%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+2.15%
SYRE - RGNX
55%
Loosely correlated
-2.45%
DNLI - RGNX
53%
Loosely correlated
+0.32%
MGNX - RGNX
53%
Loosely correlated
-1.16%
ARWR - RGNX
53%
Loosely correlated
+2.52%
KYMR - RGNX
53%
Loosely correlated
-1.21%
More